Table 2. Serum lipid concentrations at baseline and week 52 and percent changes at week 52 by study group.

Parameters		Combination		Fenofibrate		Ezetimibe
		n	Mean ± SD	n	Mean ± SD	n	Mean ± SD
TC (mg/dL)	Baseline	107	263 ± 30	52	268 ± 34	51	268 ± 28
	Week 52	69	197 ± 28	36	227 ± 34	38	233 ± 26
	%Change	69	−24.2 ± 10.6*	36	−14.8 ± 11.4*	38	−12.3 ± 7.9*
					p < 0.001		p < 0.001
TG (mg/dL)	Baseline	107	266 ± 77	52	266 ± 106	51	263 ± 107
	Week 52	69	138 ± 74	36	172 ± 93	38	224 ± 68
	%Change	69	−44.9 ± 27.3*	36	−31.8 ± 45.6*	38	−9.0 ± 24.7*
					p = 0.068		p < 0.001
HDL-C (mg/dL)	Baseline	107	47 ± 10	52	46 ± 10	51	46 ± 9
	Week 52	69	53 ± 13	36	51 ± 14	38	50 ± 16
	%Change	69	17.3 ± 17.5*	36	17.2 ± 23.9*	38	5.3 ± 16.3
					p = 0.972		p < 0.001
LDL-C (mg/dL)	Baseline	107	166 ± 27	52	173 ± 31	51	171 ± 23
	Week 52	68	117 ± 26	35	141 ± 29	38	138 ± 23
	%Change	68	−28.9 ± 15.8*	35	−17.3 ± 14.3*	38	−18.1 ± 11.5*
					p < 0.001		p < 0.001

Mean values at baseline were based on the average of multiple measurements during the pretreatment period (week −4 to week 0).

p values represent the comparison of the percent changes between the combination group and the specified group by two-sample t-test (two-sided).

^*p < 0.05 for the within-group comparison by one sample t-test.

TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol